These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 27576874)

  • 1. Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.
    Nelson SJ; Kadambi AK; Park I; Li Y; Crane J; Olson M; Molinaro A; Roy R; Butowski N; Cha S; Chang S
    Neuro Oncol; 2017 Mar; 19(3):430-439. PubMed ID: 27576874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab.
    Nelson SJ; Li Y; Lupo JM; Olson M; Crane JC; Molinaro A; Roy R; Clarke J; Butowski N; Prados M; Cha S; Chang SM
    J Neurooncol; 2016 Oct; 130(1):171-179. PubMed ID: 27535746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.
    Saraswathy S; Crawford FW; Lamborn KR; Pirzkall A; Chang S; Cha S; Nelson SJ
    J Neurooncol; 2009 Jan; 91(1):69-81. PubMed ID: 18810326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy.
    Muruganandham M; Clerkin PP; Smith BJ; Anderson CM; Morris A; Capizzano AA; Magnotta V; McGuire SM; Smith MC; Bayouth JE; Buatti JM
    Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):181-9. PubMed ID: 24986746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Metabolic Changes in 1H-MRSI Predictive for Survival in Patients With Newly Diagnosed High-grade Glioma.
    Wang MH; Roa W; Wachowicz K; Yahya A; Murtha A; Amanie J; Chainey J; Quon H; Ghosh S; Patel S
    Anticancer Res; 2022 May; 42(5):2665-2673. PubMed ID: 35489774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
    Wen Q; Jalilian L; Lupo JM; Molinaro AM; Chang SM; Clarke J; Prados M; Nelson SJ
    J Neurooncol; 2015 Jan; 121(2):331-9. PubMed ID: 25351579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.
    Deviers A; Ken S; Filleron T; Rowland B; Laruelo A; Catalaa I; Lubrano V; Celsis P; Berry I; Mogicato G; Cohen-Jonathan Moyal E; Laprie A
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):385-93. PubMed ID: 25104068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings.
    Park I; Tamai G; Lee MC; Chuang CF; Chang SM; Berger MS; Nelson SJ; Pirzkall A
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):381-9. PubMed ID: 17513061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM.
    Crawford FW; Khayal IS; McGue C; Saraswathy S; Pirzkall A; Cha S; Lamborn KR; Chang SM; Berger MS; Nelson SJ
    J Neurooncol; 2009 Feb; 91(3):337-51. PubMed ID: 19009235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme.
    Lupo JM; Essock-Burns E; Molinaro AM; Cha S; Chang SM; Butowski N; Nelson SJ
    Neuro Oncol; 2013 Apr; 15(4):480-9. PubMed ID: 23393208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Volumetric spectroscopic imaging of glioblastoma multiforme radiation treatment volumes.
    Parra NA; Maudsley AA; Gupta RK; Ishkanian F; Huang K; Walker GR; Padgett K; Roy B; Panoff J; Markoe A; Stoyanova R
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):376-84. PubMed ID: 25066215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for Grade IV glioma.
    Chan AA; Lau A; Pirzkall A; Chang SM; Verhey LJ; Larson D; McDermott MW; Dillon WP; Nelson SJ
    J Neurosurg; 2004 Sep; 101(3):467-75. PubMed ID: 15352605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring the effects of BCNU chemotherapy Wafers (Gliadel) in glioblastoma multiforme with proton magnetic resonance spectroscopic imaging at 3.0 Tesla.
    Dyke JP; Sanelli PC; Voss HU; Serventi JV; Stieg PE; Schwartz TH; Ballon D; Shungu DC; Pannullo SC
    J Neurooncol; 2007 Mar; 82(1):103-10. PubMed ID: 17031552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas.
    Li X; Jin H; Lu Y; Oh J; Chang S; Nelson SJ
    NMR Biomed; 2004 Feb; 17(1):10-20. PubMed ID: 15011246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme.
    Li Y; Lupo JM; Polley MY; Crane JC; Bian W; Cha S; Chang S; Nelson SJ
    Neuro Oncol; 2011 May; 13(5):546-57. PubMed ID: 21297128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.
    Ellingson BM; Abrey LE; Garcia J; Chinot O; Wick W; Saran F; Nishikawa R; Henriksson R; Mason WP; Harris RJ; Leu K; Woodworth DC; Mehta A; Raymond C; Chakhoyan A; Pope WB; Cloughesy TF
    Neuro Oncol; 2018 Oct; 20(11):1525-1535. PubMed ID: 29897562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
    Minniti G; Amelio D; Amichetti M; Salvati M; Muni R; Bozzao A; Lanzetta G; Scarpino S; Arcella A; Enrici RM
    Radiother Oncol; 2010 Dec; 97(3):377-81. PubMed ID: 20855119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume.
    Oh J; Henry RG; Pirzkall A; Lu Y; Li X; Catalaa I; Chang S; Dillon WP; Nelson SJ
    J Magn Reson Imaging; 2004 May; 19(5):546-54. PubMed ID: 15112303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI.
    Pirzkall A; Li X; Oh J; Chang S; Berger MS; Larson DA; Verhey LJ; Dillon WP; Nelson SJ
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):126-37. PubMed ID: 15093908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging.
    Li Y; Lupo JM; Parvataneni R; Lamborn KR; Cha S; Chang SM; Nelson SJ
    Neuro Oncol; 2013 May; 15(5):607-17. PubMed ID: 23393206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.